Skip to main content
Shuttle Pharmaceuticals Holdings, Inc. logo

Shuttle Pharmaceuticals Holdings, Inc. — Investor Relations & Filings

Ticker · SHPH ISIN · US8256933024 US Manufacturing
Open in API
Filings indexed 266 across all filing types
Latest filing 2025-02-27 Annual Report
Country US United States of America
Listing US SHPH

About Shuttle Pharmaceuticals Holdings, Inc.

https://shuttlepharma.com/

Shuttle Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company focused on developing novel therapies to improve outcomes for cancer patients. The company's mission is to enhance the effectiveness of radiation therapy (RT) by developing drugs that sensitize cancer cells to radiation while protecting adjacent healthy tissues, thereby increasing cure rates and improving quality of life. Its lead product candidate, Ropidoxuridine, is an orally available radiation sensitizer in Phase II clinical development. The pipeline also includes a portfolio of preclinical selective histone deacetylase (HDAC) inhibitors. Additionally, Shuttle is developing diagnostic technologies, including a pretreatment blood test for prostate cancer patients to help predict treatment success and inform therapeutic decisions.

Recent filings

Filing Released Lang Actions
Annual Report 2025
Annual Report Classification · 100% confidence The document is a Form 424B3 prospectus supplement that includes and references an Annual Report on Form 10-K for the fiscal year ended December 31, 2024. The text explicitly states that the Annual Report on Form 10-K is attached and incorporated by reference. The document contains detailed information typical of a 10-K filing, including business description, risk factors, financial statements, and management discussion and analysis. The length of the document (15,000 characters) and the presence of comprehensive financial and operational data confirm it is the full Annual Report, not just an announcement or a certification. Therefore, the document is classified as an Annual Report (10-K).
2025-02-27 English
Annual Report 2025
Annual Report Classification · 100% confidence The document is a Form 424B3 prospectus supplement that includes and references an Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on February 26, 2025. The text contains detailed sections typical of a 10-K filing, including business description, risk factors, management discussion and analysis, financial statements, and signatures. The document length is substantial (15,000 characters), and it contains the full annual report content rather than just an announcement or a certification. Therefore, this document is classified as an Annual Report (10-K).
2025-02-27 English
Annual Report 2025
Annual Report Classification · 100% confidence The document is a Form 424B3 prospectus supplement that references and includes the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024. The text includes detailed sections typical of a 10-K filing, such as business description, risk factors, management discussion and analysis, financial statements, and signatures. The document is lengthy (15,000 characters) and contains substantive financial and operational information, not merely an announcement or a certification. Therefore, it is classified as an Annual Report (10-K).
2025-02-27 English
Regulatory Filings 2025
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes an amendment to a Securities Purchase Agreement and waiver of rights related to warrants and convertible notes. It includes details about the amendment agreement and references exhibits attached. There are no financial statements or comprehensive financial data presented, nor is this an earnings release or annual/interim report. The document is a regulatory announcement of a material definitive agreement and related corporate actions. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2025-02-27 English
Report Publication Announcement 2025
Report Publication Announcement Classification · 95% confidence The document is a Form 8-K filed with the SEC by Shuttle Pharmaceuticals Holdings, Inc. It is dated February 26, 2025, and reports a corporate update related to the filing of the company's Annual Report on Form 10-K for the year ended December 31, 2024. The document includes a press release as an exhibit but does not contain the full annual report or detailed financial statements itself. The text explicitly states that the information is not deemed "filed" for purposes of Section 18 of the Exchange Act and may be incorporated by reference in another filing. The document length is 4233 characters, which is relatively short and consistent with an announcement rather than the full report. Therefore, this document is an announcement regarding the publication of the Annual Report (10-K), not the report itself. According to the classification rules, such announcements should be classified as Report Publication Announcement (RPA).
2025-02-26 English
Annual Report 2024
Annual Report FY 2024
2025-02-26 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.